Drug commonly used for alcoholism curbs urges of pathological gamblers

Jun 13, 2008

A drug commonly used to treat alcohol addiction has a similar effect on pathological gamblers – it curbs the urge to gamble and participate in gambling-related behavior, according to a new research at the University of Minnesota.

Seventy-seven people participated in the double-blind, placebo controlled study. Fifty-eight men and women took 50, 100, or 150 milligrams of naltrexone every day for 18 weeks. Forty percent of the 49 participants who took the drug and completed the study, quit gambling for at least one month. Their urge to gamble also significantly dropped in intensity and frequency. The other 19 participants took a placebo. But, only 10.5 percent of those who took the placebo were able to abstain from gambling. Study participants were aged 18 to 75 and reported gambling for 6 to 32 hours each week.

Dosage did not have an impact on the results, naltrexone was generally well tolerated, and men and women reported similar results.

"This is good news for people who have a gambling problem," said Jon Grant, M.D., J.D., M.P.H., a University of Minnesota associate professor of psychiatry and principal investigator of the study. "This is the first time people have a proven medication that can help them get their behavior under control."

The research is published in the June issue of the Journal of Clinical Psychiatry.

Compulsive gamblers are unable to control their behavior, and the habit often becomes a detriment in their lives, Grant said. He estimates between 1 to 3 percent of the population has a gambling problem.

While the drug is not a cure for gambling, Grant said it offers hope to many who are suffering from addiction. He also said the drug would most likely work best in combination with individual therapy.

"Medication can be helpful, but people with gambling addiction often have multiple other issues that should be addressed through therapy," he said.

Naltrexone is sold under the brand names Revia and Depade. An extended-release formulation is sold under the name Vivitrol.

Source: University of Minnesota

Explore further: Teva to lift bid for Mylan: report

Related Stories

There are no cures for the common cold

Feb 21, 2011

Americans catch an estimated 1 billion colds each year. And by this time of year, as weary cold sufferers line up at local pharmacies, it may not sound surprising that Americans spend at least $4.2 billion annually on over-the-counter ...

Dopamine-related drugs affect reward-seeking behavior

Apr 26, 2007

Drugs that adjust dopamine levels in the brain greatly affect how people react to success and failure, according to research that will be presented at the American Academy of Neurology’s 59th Annual Meeting in Boston.

Recommended for you

Teva to lift bid for Mylan: report

21 hours ago

Israeli pharmaceutical giant Teva plans to increase its bid for rival Mylan and could announce the move as soon as this week, according to a US media report Monday.

Vaccine for West Nile Virus enters human clinical trials

Jul 06, 2015

A clinical trial of a new investigational vaccine designed to protect against West Nile Virus infection will be sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes ...

FDA clears drug for leading form of cystic fibrosis

Jul 02, 2015

Federal health officials have approved a new combination drug for the most common form of cystic fibrosis, the debilitating inherited disease that causes internal mucus buildup, lung infections and early death. But it will ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.